That author of that article appears to be engaging in a bit of hyperbole. Funny how this particular vaccine is now "the most promising approach," when at the start of the trial, they called it a long shot.
This unusual study is essentially a hedge bet: it will not have the statistical power of the typical Phase 3 efficacy trial that leads to licensure, so researchers are calling it a Phase 2b. "What do you do if you want to know if something works, and the only way to do it is humans, and you don't have enough confidence to do a Phase 3 study?" asks Peggy Johnston, who heads NIAID's AIDS vaccine program. "You do an overpowered Phase 2."
There are literally dozens of HIV vaccine trials underway, and many more in the works. None of the current crop is likely to provide very strong protection, like the smallpox or polio vaccines. The question is whether they confer any useful protection, like current tuberculosis vaccines.
Some of these other remarks are quite frankly, paranoid ravings. Without going into a biology lecture, the most concise summary that I can think of is: The low-hanging fruit in vaccine research has been picked. What's left is the really hard stuff.